Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
- Japan Self-Medication Industry’s Request Letter to Health Minister Factually Incorrect: JMA Exec
October 10, 2013
- Removal of JMA, JPA Members from OTC Drug Review Council, Open Discussion Would Be Difficult, Says JMA Exec
October 9, 2013
- Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
- Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
- Diovan Issue is “Isolated Example,” Confidence in Japan Clinical Trials Not Lost: President Viehbacher of EFPIA
October 7, 2013
- JPMA Suspends Membership of Novartis Pharma in Response to Diovan Scandal
October 4, 2013
- JPMA Compliance Committee to Decide Penalties for Novartis for Diovan Case as Requested by Dr Teshirogi
October 3, 2013
- JGA Tells Members to Use Unified Trade Name “Losarhyd” for Generic Version of Combination Drug Preminent
October 1, 2013
- Generic Share Increases to 26.6% on Volume Basis in April-June 2013: JGA
October 1, 2013
- JSGM to Propose Incentive Dispensing Fee for Pharmacies That Carry Cheaper Generics, Unification of Premiums for Generic Dispensing Systems
September 26, 2013
- Japan, US Should Promote High Standards for Intellectual Property Protection and Pricing Transparency in TPP: PhRMA Executives
September 24, 2013
- JPMA Senior Managing Director Hiroaki Nakatani to Retire
September 17, 2013
- Transparency Guidelines: JPMA Says Requested Viewers’ Names, Affiliations Could Be Checked before Disclosing Individual Payment Information
September 13, 2013
- Wholesale Industry FTC Calls for Freeze on Efforts by Wholesalers to Refuse Free Services to Customers Due to Sharp Reactions from Some Pharmacies
September 4, 2013
- Min-Iren to Suspend Use of Diovan at 143 Member Hospitals
August 30, 2013
- JMA, PhRMA to Cosponsor Symposium on National Health Insurance System in September
August 29, 2013
- Insulin Treatment Improves Patients’ QOL, Marital Relationship: Healthy Japan 21 Promotion Forum, Sanofi
August 23, 2013
- Stakeholders Should Discuss Novartis’ Responsibility in the Promotion of Diovan, Large Sales: JMA Vice President
August 19, 2013
- Japanese Wholesalers Fill Role of Social Infrastructure: JPWA Report
August 14, 2013
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…